Angelantonio Maglio
Overview
Explore the profile of Angelantonio Maglio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vatrella A, Maglio A
Expert Rev Respir Med
. 2025 Jan;
19(1):1-5.
PMID: 39749409
No abstract available.
2.
Di Bona D, Bilancia M, Crimi C, Daddato M, Benfante A, Caiaffa M, et al.
Clin Exp Allergy
. 2024 Oct;
55(2):202-204.
PMID: 39390847
This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin...
3.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta V, Di Bona D, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(12):3315-3327.
PMID: 39197750
Background: Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. Although mepolizumab's short-term effectiveness is established, there is limited evidence on its ability to achieve long-term...
4.
Pelaia C, Crimi C, Benfante A, Caiaffa M, Campisi R, Candia C, et al.
Respirology
. 2024 Jun;
29(10):869-879.
PMID: 38847185
Background And Objective: Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission...
5.
Maiorano A, Lupia C, Montenegro N, Neri G, Bruni A, Garofalo E, et al.
Front Med (Lausanne)
. 2024 Mar;
11:1357362.
PMID: 38504920
Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma. Nevertheless, there is a lack of data about the use of diaphragmatic ultrasonography...
6.
Pelaia C, Giacalone A, Ippolito G, Pastore D, Maglio A, Piazzetta G, et al.
Pragmat Obs Res
. 2024 Mar;
15:45-51.
PMID: 38495680
Many different phenotypes that characterize severe asthma are supported by intricate pathomechanisms called endotypes. The latter are driven by molecular interactions, mediated by intercellular networks. With regard to the biological...
7.
Scioscia G, Tondo P, Nolasco S, Pelaia C, Carpagnano G, Caiaffa M, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445397
Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous...
8.
Pelaia C, Ferrante Bannera A, Rotundo F, Tropea F, Armentaro G, Maglio A, et al.
Int J Chron Obstruct Pulmon Dis
. 2023 Jun;
18:995-1002.
PMID: 37260547
Background: The pharmacological association umeclidinium/vilanterol (UMEC/VI) allows to implement a very effective dual bronchodilation in chronic obstructive pulmonary disease (COPD), thus optimizing bronchodilating therapy. Methods: The main purpose of our...
9.
Pelaia C, Pelaia G, Maglio A, Tinello C, Gallelli L, Lombardo N, et al.
J Clin Med
. 2023 May;
12(10).
PMID: 37240477
Asthma and nasal polyposis often coexist and are frequently intertwined by tight pathogenic links, mainly consisting of the cellular and molecular pathways underpinning type 2 airway inflammation. The latter is...
10.
Pelaia C, Benfante A, Busceti M, Caiaffa M, Campisi R, Carpagnano G, et al.
Front Immunol
. 2023 Apr;
14:1121237.
PMID: 37063895
Background: The efficacy of dupilumab as biological treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type...